| 44th week of 2014 patent applcation highlights part 57 |
| Patent application number | Title | Published |
|---|
| 20140323427 | URIDINE AND URIDINE ANALOGUES FOR TREATMENT OF SPECIFIC LUNG DISEASES, NAMELY COPD AND PULMONARY FIBROSIS - The present invention relates to the new indications of chronic obstructive pulmonary disease (COPD) and idiophathic lung fibrosis (IPF) for uridine and uridine analogues. | 2014-10-30 |
| 20140323428 | ANTINEURITIC PHARMACEUTICAL COMBINATION AND COMPOSITIONS - The present invention refers to pharmaceutical combinations of two antiepileptic substances and also to combinations of an antiepileptic and B-complex vitamins, in which the antiepileptic substances are selected from pregabalin and oxcarbazepine, and the vitamins are selected from vitamin B1 and vitamin B12. The invention also relates to pharmaceutical compositions containing said combinations and to the use of said compositions for treating neuropathic pain (NP). | 2014-10-30 |
| 20140323429 | NSAIDS-INDUCED GASTROINTESTINAL MUCOSAL DISORDER ALLEVIATOR AND MANUFACTURING METHOD THEREOF - A method of manufacturing a medical drug of alleviating damage of gastrointestinal mucosal induced by a non-steroidal anti-inflammatory drug, NSAID, the medical drug being able to induce anti-inflammatory effect of the NSAID and being able to alleviate damage induced by the NSAID includes dissolving trehalose and the NSAID into one or more solutions, so as to obtain an approximately homogenously-mixed liquid mixture of the trehalose and the NSAID; in which the liquid mixture contains an intermolecular compound with the trehalose and the NSAID; and drying the liquid mixture so as to obtain the medical drug. | 2014-10-30 |
| 20140323430 | USE OF BACTERIAL ENDOTOXINS AND LIPOTEICHOIC ACIDS TO IMPROVE POSTPARTAL HEALTH AND PRODUCTIVITY OF DAIRY COWS AND THEIR NEWBORNS - A combination of a bacterial endotoxin, in particular a lipopolysaccharide, and a lipoteichoic acid for treating or preventing a metabolic disorder or bacterial infection, or for improving milk energy efficiency in a subject. The combination may be administered separately, simultaneously or sequentially to a subject. | 2014-10-30 |
| 20140323431 | HIGH OIL CONTENT O/W EMULSIONS STABILIZED WITH A HYDROPHOBICALLY MODIFIED INULIN AND A HYDROPHILIC ACRYLIC POLYMER - The invention relates to a composition in the form of an oil-in-water emulsion and its use that contains in a physiologically acceptable medium,
| 2014-10-30 |
| 20140323432 | CARTILAGE PRODUCTION PROMOTER AND PROPHYLACTIC OR THERAPEUTIC AGENT FOR DISEASES ASSOCIATED WITH CARTILAGE DAMAGE - Disclosed is a therapy which is for preventing or treating cartilage damage and diseases associated with cartilage damage, such as arthritides and osteoarthritis, and utilizes a more effective and more safe medicinal agent. | 2014-10-30 |
| 20140323433 | METHOD FOR REHYDRATING POLYSACCHARIDE PARTICLES - Tissue and other body structures may be protected using a hydrated composition made from free-flowing substantially collagen-free rehydratable polysaccharide particles and rehydratable polysaccharide sponges. Rehydration of the particles without clumping may be carried out be dispersing the particles in a biocompatible water-miscible polar dispersant such as ethanol and combining the dispersion with sufficient aqueous solvent for the particles to convert them to a cohesive hydrogel. The hydrated composition may assist in returning an injured, inflamed or surgically repaired surface to a normal state, e.g., through one or more healing mechanisms such as modulation of an inflammatory response, phagocytosis, mucosal remodeling, reciliation or other full or partial restoration of normal function. | 2014-10-30 |
| 20140323434 | LIPID CONJUGATES IN THE TREATMENT OF CHRONIC RFHINOSINUSITIS - This invention provides a method of treating, suppressing, inhibiting, or preventing chronic rhinosinusitis in a subject comprising the step of administering to a subject a compound comprising a lipid or phospholipid moiety bond to a physiologically acceptable monomer, dimer, oligomer, or polymer, and/or a pharmaceutically acceptable salt or a pharmaceutical product thereof. This invention also provides a method of treating, suppressing, inhibiting, or preventing nasal polyps in a subject comprising the step of administering to a subject a compound comprising a lipid or phospholipid moiety bond to a physiologically acceptable monomer, dimer, oligomer, or polymer, and/or a pharmaceutically acceptable salt or a pharmaceutical product thereof. | 2014-10-30 |
| 20140323435 | Thienopyrimidine Inhibitors of Atypical Protein Kinase C - The present application provides a compound of formula (I) | 2014-10-30 |
| 20140323436 | SUBSTITUTED BENZENE FUNGICIDES - Disclosed are compounds of Formula 1, including all geometric and stereoisomers, N-oxides, and salts thereof, | 2014-10-30 |
| 20140323437 | Use of Metallocene Compounds for Cancer Treatment - Metallocene compounds and pharmaceutical compositions containing these metallocene compounds are disclosed and described. Methods of treating cancer employing such metallocene compounds and pharmaceutical compositions also are provided. | 2014-10-30 |
| 20140323438 | COMPOUNDS AND METHODS FOR THE PREVENTION AND TREATMENT OF TUMOR METASTASIS AND TUMORIGENESIS - The disclosure provides compounds for reducing the prevalence of the perinucleolar compartment in cells, for example, of formula (I), wherein R | 2014-10-30 |
| 20140323439 | THERAPIES FOR HEMATOLOGIC MALIGNANCIES - The invention provides methods that relate to a novel therapeutic strategy for the treatment of hematological malignancies and inflammatory diseases. In particular, the method comprises administration of a compound of formula A, | 2014-10-30 |
| 20140323440 | AMINO-PYRIDINE-CONTAINING SPLEEN TYROSINE KINASE (SYK) INHIBITORS - The invention provides certain amino-pyridine-containing compounds of the Formula (I) | 2014-10-30 |
| 20140323441 | Purine derivatives for the treatment of viral infections - The present invention relates to purine derivatives of formula (I), processes for their preparation, pharmaceutical compositions, and their use in treating viral infections. | 2014-10-30 |
| 20140323442 | Small Molecule Modulators of pRb Inactivation - The present invention provides a small molecule treatment of diseases/conditions caused by a virus carrying a viral oncoprotein. In one embodiment, the virus which carries the viral oncoprotein is HPV. The small molecule useful herein includes thiadiazolin-3,5-dione compounds having an optionally substituted aryl group bound to one nitrogen atom of said thiadiazolin-3,5-dione compound. The small molecules may also be administered with a compound which inhibits binding of HPV E6 to p53. In one embodiment, the thiadiazolin-3,5-dione compound has formula (I), or a pharmaceutically acceptable salt, prodrug, solvate, or metabolite thereof, wherein R | 2014-10-30 |
| 20140323443 | TIGECYCLINE FORMULATIONS - A tigecycline composition includes tigecycline and arginine, where the composition is a solid. The solid composition may be made by forming a liquid mixture including a solvent, tigecycline and arginine, and lyophilizing the liquid mixture. | 2014-10-30 |
| 20140323444 | ANTI-INFLAMMATORY AND ANTIDIABETIC AGENTS - The present invention relates to compounds, | 2014-10-30 |
| 20140323445 | Salicylic Acid Gel - A salicylic acid gel contains salicylic acid, a thickener, and a stabilizer compound. The gel may be diluted and/or incorporated into final skin care products. | 2014-10-30 |
| 20140323446 | USE OF ZILEUTON FOR THE TREATMENT OF NASAL POLYPS IN CYSTIC FIBROSIS PATIENTS - The present invention provides methods of treating nasal polyps in cystic fibrosis patients using zileuton. The present invention also provides methods of treating nasal polyps in cystic fibrosis patients using zileuton in combination with surgical debridement and/or steroid treatment. | 2014-10-30 |
| 20140323447 | HETEROAROMATIC COMPOUNDS, MEDICAMENTS CONTAINING SAID COMPOUNDS, USE THEREOF AND PROCESSES FOR THE PREPARATION THEREOF - The present invention relates to compounds of general formula (I) | 2014-10-30 |
| 20140323448 | sGC STIMULATORS - Compounds of Formula I are described. They are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds may be useful for treating, preventing or managing various disorders that are herein disclosed. | 2014-10-30 |
| 20140323449 | ENEMA COMPOSITION FOR TREATMENT OF ULCERATIVE COLITIS HAVING LONG TERM STABILITY - Long term storage stable budesonide-containing solutions are disclosed. The solutions can include budesonide or a pharmaceutically acceptable salt thereof, cromolyn sodium, antioxidizing agent, benzoic acid, and a pharmaceutically acceptable fluid including propylene glycol and water. Kits including the long term storage stable budesonide-containing solutions and methods of treating ulcerative colitis are also disclosed. | 2014-10-30 |
| 20140323450 | COMBINATION COMPOSITIONS AND METHODS OF TREATMENT - The instant invention describes macrocyclic compounds having therapeutic activity, and methods of treating disorders such as methods of modulating cellular proliferation processes, and methods of treating disease, disorders, and symptoms thereof. | 2014-10-30 |
| 20140323451 | METHODS FOR ADMINISTERING CORTICOSTEROID FORMULATIONS - Described here are methods for the treatment of respiratory conditions using nebulized corticosteroids. The methods administer a dose of corticosteroid twice a day or more with nebulization times of 5 minutes or less. The faster nebulization times improve patient compliance. The methods also employ a lower corticosteroid dose while achieving therapeutic efficacy similar to commercially available formulations. This results in improved patient safety by reducing the systemic exposure of the corticosteroid. | 2014-10-30 |
| 20140323452 | LIPOBALANCED LONG CHAIN TESTOSTERONE ESTERS FOR ORAL DELIVERY - The present disclosure is drawn to oral pharmaceutical compositions and dosage forms containing select testosterone esters and related methods. In one embodiment of the present invention, an oral pharmaceutical composition for administration to subjects in need of testosterone is provided. The composition comprises a testosterone ester and a pharmaceutically acceptable carrier. The testosterone ester can have the structure | 2014-10-30 |
| 20140323453 | LIPOBALANCED LONG CHAIN TESTOSTERONE ESTERS FOR ORAL DELIVERY - The present disclosure is drawn to oral pharmaceutical compositions and dosage forms containing select testosterone esters and related methods. In one embodiment of the present invention, an oral pharmaceutical composition for administration to subjects in need of testosterone is provided. The composition comprises a testosterone ester and a pharmaceutically acceptable carrier. The testosterone ester can have the structure | 2014-10-30 |
| 20140323454 | ANAESTHETIC COMPOSITION - A stable anaesthetic composition is described which is particularly suitable for use in cats and dogs. The composition comprises an aqueous solution of an anaesthetically effective amount of water soluble cyclodextrin or a cyclodextrn derivative complex of alfaxalone and a bugger, excluding phosphate buffter pH 7.0, 0.1 M mixed as defined in the British Pharmadopoeia 1998, such that the pH of the solution is from 6.0-8.0. | 2014-10-30 |
| 20140323455 | METHODS FOR PRESERVING PHOTORECEPTOR CELL VIABILITY FOLLOWING RETINAL DETACHMENT - Provided are methods for maintaining the viability of photoreceptor cells following retinal detachment. The viability of photoreceptor cells can be preserved by administering a hydrophilic bile acid (e.g., UDCA or TUDCA) to a mammal having an eye with a detached retina. Administration of the hydrophilic bile acid maintains the viability of the photoreceptor cells until such time that the retina becomes reattached to the underlying retinal pigment epithelium and choroid, thereby minimizing the loss of vision or visual acuity, which otherwise may occur as a result of the retinal detachment. | 2014-10-30 |
| 20140323456 | ESTERS OF DCPLA AND METHODS OF TREATMENT USING THE SAME - The present disclosure relates to esters of 8-[2-(2-pentyl-cyclopropylmethyl)cyclopropyl]-octanoic acid (“DCPLA”). The disclosure further relates to compositions, kits, and methods for treatment using the esters. | 2014-10-30 |
| 20140323457 | BETA-O/S/N FATTY ACID BASED COMPOUNDS AS ANTIBACTERIAL AND ANTIPROTOZOAL AGENTS - The present invention relates to beta-O/S/N fatty acids and derivatives thereof, in particular the compounds of formula (I) as described and defined herein, and their pharmaceutical use, including their use in the treatment or prevention of bacterial as well as protozoan infections, in particular the treatment or prevention of infections with Gram-positive and/or Gram-negative bacteria and infectious diseases caused by and/or related to Gram-positive and/or Gram-negative bacteria. The invention further relates to the use of these compounds for preventing or eliminating biofilms. | 2014-10-30 |
| 20140323458 | SUBSTITUTED ALIPHANES, CYCLOPHANES, HETERAPHANES, HETEROPHANES, HETERO-HETERAPHANES AND METALLOCENES USEFUL FOR TREATING HCV INFECTIONS - The present disclosure provides substituted aliphanes, cyclophanes, heteraphanes, heterophanes, hetero-heteraphanes and metallocenes, of Formula I | 2014-10-30 |
| 20140323459 | ISOXAZOLE BETA-LACTAMASE INHIBITORS - β-Lactamase inhibitor compounds (BLIs) are disclosed, including compounds that have activity against class A, class C or class D β-lactamases. Methods of manufacturing the BLIs, and uses of the compounds in the preparation of pharmaceutical compositions and antibacterial applications are also disclosed. | 2014-10-30 |
| 20140323460 | Methods for Using Carboxamide, Sulfonamide and Amine Compounds - Disclosed are uses of carboxamide, sulfonamide and amine compounds for the treatment and amelioration of disorders and conditions related to oxidative stress, mitochondrial dysfunction, free radical damage and metabolic inefficiency, among others. Also described are methods for increasing exercise endurance, exercise efficiency and aerobic workload using the compounds described herein. | 2014-10-30 |
| 20140323461 | Phenyl-Substituted Nicotinic Ligands, and Methods of Use Thereof - Disclosed are compounds and methods of using them to treat a disorder selected from the group consisting of addiction, pain, obesity, schizophrenia, epilepsy, mania and manic depression, anxiety, Alzheimer's disease, learning deficit, cognition deficit, attention deficit, memory loss, Lewy Body Dementia, Attention Deficit Hyperactivity Disorder (ADHD), Parkinson's disease, Huntington's disease, Tourette's syndrome, amyotrophic lateral sclerosis, inflammation, stroke, spinal cord injury, dyskinesias, obsessive compulsive disorder, chemical substance abuse, alcoholism, memory deficit, pseudodementia, Ganser's syndrome, migraine pain, bulimia, premenstrual syndrome or late luteal phase syndrome, tobacco abuse, post-traumatic syndrome, social phobia, chronic fatigue syndrome, premature ejaculation, erectile difficulty, anorexia nervosa, autism, mutism, trichotillomania, hypothermia, and disorders of sleep. | 2014-10-30 |
| 20140323462 | AZETIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE - Provided are compounds of Formula I, | 2014-10-30 |
| 20140323463 | PYRAZINECARBOXAMIDE COMPOUND | 2014-10-30 |
| 20140323464 | KINASE INHIBITORS - Provided herein are kinase inhibiting compounds and methods of using the same. | 2014-10-30 |
| 20140323465 | HCV PROTEASE INHIBITORS AND USES THEREOF - The present invention provides compounds, pharmaceutically acceptable compositions thereof, and methods of using the same. | 2014-10-30 |
| 20140323466 | THIENYL [3,2-D] PYRIMIDIN-4-ONE COMPOUNDS, PREPARATION METHOD, PHARMACEUTICAL COMPOSITIONS AND USE THEREOF - Disclosed are new thienyl[3,2-d]pyrimidin-4-one compounds shown as the general formula (I), preparation method, pharmaceutical compositions and pharmacological use thereof. The compounds are strong DPPIV (dipeptide peptidase IV) inhibitors and can treat type II diabetes through well inhibiting DPPIV indirectly increasing the content of GLP-1 in vivo and inducing a series of physiological actions in vivo. Therefore, the compounds could be developed as new promising drugs for treating diabetes. | 2014-10-30 |
| 20140323467 | THERAPEUTIC COMPOUNDS AND COMPOSITIONS - Compounds and compositions comprising compounds that modulate pyruvate kinase M2 (PKM2) are described herein. Also described herein are methods of using the compounds that modulate PKM2 in the treatment of cancer. | 2014-10-30 |
| 20140323468 | ALDOSTERONE SYNTHASE INHIBITORS - The present invention relates to compounds of formula (I): | 2014-10-30 |
| 20140323469 | 1,4 OXAZEPINES AS BACE1 AND/OR BACE2 INHIBITORS - This invention relates to compounds of the formula | 2014-10-30 |
| 20140323470 | KINASE INHIBITORS - Compounds of formula (I) and pharmaceutically acceptable salts thereof: | 2014-10-30 |
| 20140323471 | POLYMORPHIC FORMS OF IVABRADINE HYDROCHLORIDE - Stable crystalline Form II and stable crystalline Form III of ivabradine hydrochloride and processes for their preparation are disclosed. | 2014-10-30 |
| 20140323472 | METHODS AND COMPOSITIONS FOR THE DELIVERY OF A THERAPEUTIC AGENT - The present invention provides a liquid pharmaceutical composition comprising a therapeutic agent and an alkoxy-polyethylene glycol, for example, methoxy-polyethylene glycol, for administration of the therapeutic agent to the mammal. The compositions can be applied to a membrane, for example, a nasal membrane during intranasal administration. The invention also provides methods of administering such compositions to a mammal. | 2014-10-30 |
| 20140323473 | COMPOUNDS AND METHODS TO TREAT ORGANOPHOSPHORUS POISONING - Organophosphate (OP) nerve agents and pesticides are potent inhibitors of acetylcholinesterase (AChE). Though oxime nucleophiles can reactivate an AChE-phosphyl adduct, the adduct can undergo a reaction called aging, leading to an aged-AChE adduct. The invention provides compounds and methods that can be used to reactivate an aged-AChE adduct. Such compounds and methods are useful to counteract organophosphorus poisoning. | 2014-10-30 |
| 20140323474 | Hexahydropyrano[3,4-d][1,3]Thiazin-2-Amine Compounds - The present invention provides compounds of Formula I, and the tautomers thereof, and the pharmaceutically acceptable salts of the compounds and tautomers, wherein the compounds have the structure | 2014-10-30 |
| 20140323475 | EP1 RECEPTOR LIGANDS - The present invention belongs to the field of EP1 receptor ligands. More specifically it refers to compounds of general formula (I) having great affinity and selectivity for the EP1 receptor. The invention also refers to the process for their preparation, to their use as medicament for the treatment and/or prophylaxis of diseases or disorders mediated by the EP1 receptor as well as to pharmaceutical compositions comprising them. | 2014-10-30 |
| 20140323476 | PEPTIDE DEFORMYLASE INHIBITORS - The present invention relates to {2-(alkyl)-3-[2-(5-fluoro-4-pyrimidinyl)hydrazino]-3-oxopropyl}hydroxyformamide compounds of Formula (I): | 2014-10-30 |
| 20140323477 | SERINE/THREONINE KINASE INHIBITORS - Compounds having the formula I, or a pharmaceutically acceptable salt thereof, wherein R | 2014-10-30 |
| 20140323478 | SERINE/THREONINE KINASE INHIBITORS - Compounds having the formula I, or a pharmaceutically acceptable salt thereof, wherein R | 2014-10-30 |
| 20140323479 | 1H-PYRAZOLO[3,4-B]PYRIDINES AND THERAPEUTIC USES THEREOF - Provided herein are compounds according to Formula I and pharmaceutically acceptable salts thereof, and compositions comprising the same, for use in various methods, including treating cancers such as colon, ovarian, pancreatic, breast, liver, prostate and hematologic cancers: | 2014-10-30 |
| 20140323480 | Imidazopyridine Derivatives As PI3 Kinase - This invention relates to the use of imidizopyridine derivatives for the modulation, notably the inhibition of the activity or function of the phosphoinositide 3′ OH kinase family (hereinafter PI3 kinases), suitably, PI3Kα, PI3Kδ, PI3Kβ, and/or PI3Kγ. Suitably, the present invention relates to the use of imidizopyridines in the treatment of one or more disease states selected from: autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, allergy, asthma, pancreatitis, multiorgan failure, kidney diseases, platelet aggregation, cancer, sperm motility, transplantation rejection, graft rejection and lung injuries. More suitably, the present invention relates to PI3Kβ selective imidizopyridine compounds for treating cancer. | 2014-10-30 |
| 20140323481 | 3-CYANOARYL-1H-PYRROLO[2,3-B]PYRIDINE DERIVATIVES - Compounds of the formula (I) in which R | 2014-10-30 |
| 20140323482 | SUBSTITUTED PIPERIDINES AS HDM2 INHIBITORS - The present invention provides a compound of Formula I (The formula should be inserted here) as described herein or a pharmaceutically acceptable salt or solvate thereof. The representative compounds are useful as inhibitors of the HDM2 protein. Also disclosed are pharmaceutical compositions comprising the above compounds and potential methods of treating cancer using the same. | 2014-10-30 |
| 20140323483 | TYPE III SECRETION INHIBITORS, ANALOGS AND USES THEREOF - The invention, in some aspects, relates to compounds and compositions useful for inhibiting Type III secretion systems in pathogenic bacteria, such as | 2014-10-30 |
| 20140323484 | Pharmaceutically Active Pyrazine Derivatives - The invention provides compounds which inhibit or modulate the activity of Chk-1 kinase and which are useful in the treatment of cancer. The compounds have the general formula (1): | 2014-10-30 |
| 20140323485 | N-Substituted Heterocyclyl Carboxamides - A compound of Formula I | 2014-10-30 |
| 20140323486 | HETEROCYCLIC UREA COMPOUNDS - The present invention provides a compound of the following formula, racemates, enantiomers and salts thereof. Also provided is the use of these compounds as antibacterials, compositions comprising them and processes for their manufacture. | 2014-10-30 |
| 20140323488 | DISUBSTITUTED TRIAZINE DIMERS FOR TREATMENT AND/OR PREVENTION OF INFECTIOUS DISEASES - The present invention relates to novel compounds (I) containing two disubstituted triazine rings covalently linked by an organic linker, thereby creating dimers. These compounds show activity against the causative infective agents of infectious diseases such as African trypanosomiasis, Chagas disease, Leishmaniasis, Malaria and HIV. The invention further relates to the prevention and/or treatment of these diseases. | 2014-10-30 |
| 20140323489 | HYBRID NECROPTOSIS INHIBITORS - The present invention relates to heterocyclic compounds (e.g., compounds described by Formula (I)) and pharmaceutically acceptable salts thereof. The invention also features pharmaceutical compositions that include these compounds and their use in therapy for treating conditions in which necroptosis is likely to play a substantial role. The heterocyclic compounds described herein can also achieve improved activity and selectivity towards RIP1 and/or RIP3. | 2014-10-30 |
| 20140323490 | POLYCYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS - Polycyclic heteroaryl substituted triazoles and pharmaceutical compositions containing the compounds are disclosed as being useful in inhibiting the activity of the receptor protein tyrosine kinase Axl. Methods of using the compounds in treating diseases or conditions associated with Axl activity are also disclosed. | 2014-10-30 |
| 20140323491 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES SOLID - The present invention relates to toluenesulfonic acid addition salt crystals of specific substituted heterocycle fused gamma-carbolines, the method of making and using such crystals. | 2014-10-30 |
| 20140323492 | CCR2 RECEPTOR ANTAGONISTS - The present invention relates to novel antagonists for CCR2 (CC chemokine receptor 2) and their use for providing medicaments for treating conditions and diseases, especially pulmonary diseases like asthma and COPD. | 2014-10-30 |
| 20140323493 | METHOD OF TREATING ATRIAL FIBRILLATION - The present invention relates to a method for the treatment or prevention of atrial fibrillation and/or atrial flutter comprising coadministration of a synergistically therapeutic amount of dronedarone or a pharmaceutically acceptable salt or salts thereof and a synergistically therapeutic amount of ranolazine or a pharmaceutically acceptable salt or salts thereof. Also provided are methods for modulating ventricular and atrial rhythm and rate. This invention also relates to pharmaceutical formulations that are suitable for such combined administration. | 2014-10-30 |
| 20140323494 | N-OXIDES OF N-PHENYL-2-PYRIMIDINE-AMINE DERIVATIVES - The invention relates to N-phenyl-2-pyrimidine-amine derivatives in which at least one nitrogen atom carries an oxygen atom to form the corresponding N-oxides, to processes for the preparation thereof, to pharmaceutical compositions comprising those compounds, and to the use thereof in the preparation of pharmaceutical compositions for the therapeutic treatment of warm-blooded animals, including humans. | 2014-10-30 |
| 20140323495 | Stabilized Amorphous Forms of Imatinib Mesylate - The invention relates to the stabilized amorphous form of the methanesulfonic acid addition salt of 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-(pyridin-3-yl)-pyrimidin-2-ylamino)-phenyl]-benzamide, pharmaceutical compositions such as capsules or tablets containing this form, the use of such form in diagnostic methods or, preferably, for the therapeutic treatment of warm-blooded animals, especially humans, and the use of formulation principles stabilizing the amorphous form of Imatinib mesylate as an intermediate for the preparation of pharmaceutical compositions. | 2014-10-30 |
| 20140323496 | COMPOSITIONS AND METHODS FOR REDUCTION OF AMYLOID-BETA LOAD - The present invention relates to methods and compositions for modulating levels of amyloid-β peptide (Aβ) exhibited by non-neuronal (i.e., peripheral) cells, fluids, or tissues. The invention also relates to modulation of Aβ levels via selective modulation (e.g., inhibition) of γ-secretase activity. The invention also relates to methods of preventing, treating or ameliorating the symptoms of a disorder, including but not limited to an Aβ-related disorder, by administering a compound that results in the modulation of γ-secretase in a non-neuronal tissue, either directly or indirectly to prevent, treat or ameliorate the symptoms of a brain Aβ disorder, such as Alzheimer's disease. | 2014-10-30 |
| 20140323497 | METHODS AND FORMULATIONS OF TREATING THROMBOSIS WITH BETRIXABAN AND A P-GLYCOPROTEIN INHIBITOR - This invention is directed to methods of inhibiting coagulation or treating thrombosis using a factor Xa inhibitor and a P-glycoprotein (Pgp) inhibitor. The invention is also directed to formulations used in the methods. | 2014-10-30 |
| 20140323498 | SOLID STATE FORMS OF VILAZODONE AND VILAZODONE HYDROCHLORIDE - The present invention provides solid state forms of Vilazodone and Vilazodone hydrochloride, processes for preparing these solid state forms, and pharmaceutical compositions comprising one or more of these solid state forms | 2014-10-30 |
| 20140323499 | OXAZOLONE AND PYRROLIDINONE-SUBSTITUTED ARYLAMIDES AS P2X3 AND P2X2/3 ANTAGONISTS - Compounds of the formula I: | 2014-10-30 |
| 20140323500 | NADPH OXIDASE 4 INHIBITORS AND USE THEREOF - The present invention is related to Nox4 inhibitors, pharmaceutical composition thereof and to their use for the treatment and/or prevention of osteoporosis or an osteoclastogenesis dysfunction, in particular osteoporotic and pre-osteoporotic osteoclastogenesis dysfunction. | 2014-10-30 |
| 20140323501 | AMINO-PROPYLENE-GLYCOL DERIVATIVES, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITION AND USE THEREOF - Immune-modulators of formula (I) below are prepared: | 2014-10-30 |
| 20140323502 | HETEROCYCLIC SULFONAMIDES, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF - The invention is directed to a class of compounds, including the pharmaceutically acceptable salts of the compounds, having the structure of formula I: | 2014-10-30 |
| 20140323503 | INHIBITORS OF PHOSPODIESTERASES 11 (PDE11) AND METHODS OF USE TO ELEVATE CORTISOL PRODUCTION - The present intervention generally relates to compositions comprising a PDE11 inhibitor for increasing cortisol levels in a subject, or for increasing the production of cortisol from adenocortical cells in a subject. Aspects of the invention relate to the use of a PDE11 inhibitor in a method of treatment of low cortisol levels and/or adrenal insufficiency in a subject, or a method of treating a disease or disorders associated with adrenal insufficiency. Aspects of the invention relate to PDE11 inhibitors belonging to compounds of formula (I)-(VI), and their use alone or in combination with long-term corticosteroid treatment to elevate cortisol levels in a subject, and/or to treat adrenal insufficiency. Another aspect relates to kits comprising PDE11 inhibitors for administration to a subject, pharmaceutical compositions comprising compounds of formula (I)-(VI) for use in methods to increase cortisol levels and/or treat adrenal insufficiency, and their use as an adjuvant for treatment of cancer or other disorders such as psychiatric diseases where elevating cortisol levels would be beneficial to the subject. | 2014-10-30 |
| 20140323504 | Pyrazolo[4,3-c]Pyridine Derivatives As Kinase Inhibitors - The present invention relates to compounds of formula (I) | 2014-10-30 |
| 20140323505 | ORAL RINSE COMPOSITION AND METHOD TO DELIVER ENERGY SUPPLEMENTS - An oral rinse composition that comprises an aqueous solution that includes a high molecular weight polymer and an energy supplement that stimulates central nervous system activity. | 2014-10-30 |
| 20140323506 | COMBINATION - The present invention relates to a method of treating cancer in a human and to pharmaceutical combinations useful in such treatment. In particular, the method relates to a cancer treatment method that includes administering 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methylbenzenesulfonamide, or a pharmaceutically acceptable salt thereof, and N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)6,8-dimethy;-2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide, or a pharmaceutically acceptable salt or solvate thereof, to a human in need thereof. | 2014-10-30 |
| 20140323507 | MYCOPHENOLIC ACID ANALOGUES AS ANTI-TUMOR CHEMOSENSITIZING AGENTS - In some embodiments, the present invention provides methods of treating a tumor in a subject. In some embodiments, the methods may include a step of administering to the subject a therapeutic composition that comprises: (a) mycophenolic acid, an analogue thereof, or a derivative thereof; and (b) at least one anti-neoplastic agent. In some embodiments, the antineoplastic agent may include at least one of 5-fluouracil (5-FU), paclitaxel, oxaliplatin, doxorubicin, etoposide, irinotecan, bleomycin, imiquimod, 13-cis-retinoic acid, and combinations thereof. In some embodiments, the relative concentrations of the mycophenolic acid, the analogue thereof, or the derivative thereof, and the at least one anti-neoplastic agent correspond to their respective IC50 values. In some embodiments, the methods of the present invention may be used to treat tumors associated with at least one of an oral cancer, a skin cancer, a breast cancer, a prostate cancer, precancerous lesions thereof, hyperplastic lesions thereof, and benign tumors thereof. | 2014-10-30 |
| 20140323508 | NOVEL COMPOUNDS - The invention provides compounds of formula (I): Said compounds being modulators of Kv3 channels and of use in the prophylaxis or treatment of related disorders. | 2014-10-30 |
| 20140323509 | 2-HETEROCYCLYLAMINOALKYL-(P-QUINONE) DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES - Methods of treating or suppressing oxidative stress disorders including mitochondrial diseases, impaired energy processing disorders, neurodegenerative diseases and diseases of aging are disclosed, as well as compounds useful in the methods of the invention, such as 2-heterocyclylaminoalkyl-(p-quinone) derivatives. | 2014-10-30 |
| 20140323510 | SUBSTITUTED ARYLCYCLOPENTENES AS THERAPEUTIC AGENTS - Disclosed herein is a compound of the formula | 2014-10-30 |
| 20140323511 | CHEMOTHERAPEUTIC FOR INDUCING AN MSH2 DEPENDENT APOPTOTIC PATHWAY - Active compounds include compounds of Formula I and Formula II are described: | 2014-10-30 |
| 20140323512 | Acrylic Polymer Formulations - Disclosed herein are oral solid dosage forms comprising purified neutral acrylic polymer, methods of treating a disease or condition using the same, and methods of preparing the same. | 2014-10-30 |
| 20140323513 | Chemotherapeutic Compositions and Methods for Treating Human Gliomas - Disclosed are compound for targeting chemotherapeutic agents to mammalian mitochondria. Also disclosed are monoamine oxidase-specific compositions, and methods of using them for the selective therapy of mammalian cancers, and in particular, in the treatment of human gliomas. Also disclosed are methods employing the novel targeted chemotherapeutics with one or more conventional anti-cancer therapies, including, for example, radiotherapy, or multi-drug regimens. | 2014-10-30 |
| 20140323514 | MULTI-ARM POLYMER PRODRUGS - Provided herein are water-soluble prodrugs, compositions comprising such prodrugs, and related methods of making and administering the same. The prodrugs of the invention comprise a water-soluble polymer having three or more arms, at least three of which are typically covalently attached to an active agent, e.g., a small molecule. The conjugates of the invention provide an optimal balance of polymer size and structure for achieving improved drug loading, since the conjugates of the invention possess three or more active agents releasably attached to a multi-armed water-soluble polymer. The prodrugs of the invention are therapeutically effective, and exhibit improved properties in-vivo when compared to unmodified parent drug. | 2014-10-30 |
| 20140323516 | METHODS OF TREATING DERMATOLOGICAL DISORDERS AND INDUCING INTERFERON BIOSYNTHESIS WITH SHORTER DURATIONS OF IMIQUIMOD THERAPY - Pharmaceutical formulations and methods for the topical and/or transdermal delivery of imiquimod, including creams, ointments and pressure-sensitive adhesive compositions to treat dermatological disorders, namely, viral infections, such as Type I or Type II Herpes simplex infections and genital and perianal warts, actinic deratosis and superficial basal cell carcinoma, and to induce interferon biosynthesis to achieve an antiviral effect, with shorter durations of therapy, than currently approved for imiquimod by the Food & Drug Administration (“FDA”). | 2014-10-30 |
| 20140323517 | COMPOSITIONS AND METHODS FOR INJECTION OF A BIODEGRADABLE POLYMER-BASED DELIVERY SYSTEM - A method for administering a polymeric-based delivery system to a subject is described. The method comprises contacting a housing comprising a polymer-based delivery system with a heat-generating component for a period of time; and injecting the delivery system into the subject. | 2014-10-30 |
| 20140323518 | NOVEL ESTROGEN RECEPTOR LIGANDS - Compounds of formula (I) or a pharmaceutically acceptable ester, amide, carbamate or salt thereof, including a salt of such an ester, amide or carbamate in which R | 2014-10-30 |
| 20140323519 | HETEROCYCLIC COMPOUNDS AS B-RAF INHIBITORS FOR TREATMENT OF CANCER - This invention relates to novel heterocyclic compounds that are useful for treating cancer and other cellular proliferative diseases and/or disorders associated with B-Raf activity. The compounds of the invention may be illustrated by the Formula (I). (Formula (I)) | 2014-10-30 |
| 20140323520 | Compositions and Methods for Increasing Proliferation of Adult Salivary Stem Cells - The present disclosure provides methods of increasing proliferation of adult salivary stem cells. The methods include contacting adult salivary stem cells in vivo, in vitro, or ex vivo with an aldehyde dehydrogenase (ALDH) agonist. Increasing proliferation of adult salivary stem cells can be carried out to provide for an increase in the number of adult salivary stem cells in an indi vidual undergoing radiotherapy for head and neck cancer. | 2014-10-30 |
| 20140323521 | PHARMACEUTICAL COMPOSITIONS AND ADMINISTRATIONS THEREOF - The present invention relates to the use of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide, solids forms, and pharmaceutical compositions thereof for the treatment of CFTR mediated diseases, particularly cystic fibrosis, in patients possessing specific genetic mutations. | 2014-10-30 |
| 20140323522 | Method of Treating Cancer - This invention is directed to the treatment of cancer, particularly castration-resistant prostate cancer and bone metastases, with a dual inhibitor of MET and VEGF. | 2014-10-30 |
| 20140323523 | Positive allosteric modulators of nicotinic acetylcholine receptor - The present invention relates to compounds useful in therapy, to compositions comprising said compounds, and to methods of treating diseases comprising administration of said compounds. The compounds referred to are positive allosteric modulators (PAMs) of the nicotinic acetylcholine α7 receptor. | 2014-10-30 |
| 20140323524 | Anti-Proliferative Compounds and Methods for Using the Same - Disclosed herein are anti-proliferative compounds which find use in inhibiting the growth of cancer cells. Also provided herein are methods for using these compounds for inhibiting growth of cancer cells. Also provided herein are methods for using these compounds for treating a subject for hyperproliferative conditions, including without limitation the treatment of hematopoietic cancers. | 2014-10-30 |
| 20140323525 | Fungicidal Active Substance Combinations Containing Trifloxystrobin - What are described are novel active compound combinations comprising a known oxime ether derivative (trifloxystrobin) and imidacloprid, which combinations are highly suitable for controlling phytopathogenic fungi and insects. | 2014-10-30 |
| 20140323526 | NUTRITIONAL SUPPLEMENTS - A process for improving the health of a subject, the process comprising orally administering a composition comprising hydroxytyrosol to the subject to provide the subject with a daily dose of about 0.1 to about 750 .mu.g hydroxytyrosol per kg of body weight, and a dietary supplement in dosage unit form for oral administration, the dosage unit form comprising a composition containing about 1 microgram to about 50 milligrams hydroxytyrosol or an ester or salt thereof. | 2014-10-30 |
| 20140323527 | ARYLOXY AMINE COMPOUNDS AND THEIR USE AS SODIUM CHANNEL MODULATORS - The present invention relates generally to the field of therapeutic treatment and compounds having utility therefor, in particular the therapy or management of conditions associated with excessive, unwanted or undesirable sodium ion passage through cellular membranes via voltage-gated sodium channels. In one embodiment the invention is concerned with the treatment of neuropathic pain. The invention contemplates to aryloxy-substituted amines, as sodium channel blockers or modulators. In further embodiments, the invention also relates to compounds which may advantageously have dual sodium channel blocker/modulating and antioxidative (free-radical scavenging) effects. Methods for their manufacture and compositions containing the compounds are also contemplated. | 2014-10-30 |
| 20140323528 | INSECTICIDAL 2-METHOXYBENZAMIDE DERIVATIVES - The present invention relates to novel triazole derivatives of formula (I) having insecticidal activity, to processes and intermediates for preparing them, to insecticidal, acaricidal, nematicidal or molluscicidal compositions comprising them and to methods of using them to combat and control insect, acarine, nematode or mollusc pests wherein R | 2014-10-30 |
